OBJECTIVE
To analyze the current state of cardiovascular diseases (CVD) Prevention Program as an integral part of the federal project «Treatment of CVD» and relevant regional programs in certain subjects of the Russian Federation and propose directions for its improvement.
MATERIAL AND METHODS
We developed a questionnaire that includes 30 questions affecting the main parameters of implementation of CVD prevention in constituent entities of the Russian Federation. Survey and subsequent structured interviews were conducted with experts (chief specialists — cardiologists, neurologists or therapists) of 9 constituent entities of the Russian Federation (Republic of Karelia, Komi Republic, Volgograd Region, Altai Territory, Kemerovo Region, Samara Region, Nizhny Novgorod Region, Ryazan Region, Moscow Region).
RESULTS
The CVD prevention program has been implemented in constituent entities of the Russian Federation selected for the study since March-June 2020 at the expense of federal budget subsidies and a small share of regional budgets (<20%). After 2021, patients were provided with medicines for 2 years after establishing the diagnosis and/or surgical intervention. In most constituent entities of the Russian Federation, there is an increase in the number of patients included in the CVD Prevention Program for the period from 2020 to 2021. There were high actual rates of follow-up of patients with previous stroke, myocardial infarction, coronary artery bypass grafting, percutaneous coronary interventions and catheter ablation (min 74.9%) and their provision with drugs (min 82.6%) in 2021. In some regions, patients receive necessary drugs immediately after discharge from the hospital. The regions procured nearly all medicines included into the list approved by the Order of the Ministry of Health of Russia dated September 24, 2021 No. 936n «On approval of medicines for outpatient treatment of patients with previous stroke, myocardial infarction, coronary artery bypass grafting, percutaneous coronary interventions and catheter ablation for cardiovascular diseases».
CONCLUSION
The measures for improving the effectiveness of the CVD Prevention Program as an integral part of the federal project «Treatment of CVD» and relevant regional programs should include outpatient cardiology centers, correction of drug therapy depending on indications, availability of all diagnostic methods, introduction of electronic receipt, strict control over follow-up of patients and achievement of target parameters, improvement of regional medical information systems and register of patients, etc. It is necessary to work out the mechanisms for lifelong provision of medicines for outpatient treatment of patients included in the CVD Prevention Program. It is also necessary to define the criteria and procedure for inclusion (and exclusion) of drugs into this program. Moreover, there is a reasonable need to expand the range of drugs and diseases in the CVD Prevention Program.
